Durom(R) Hip Resurfacing System Multicenter Trial

Inclusion Criteria: * Patient selection without bias to race or gender * Patient is greater than or equal to 18 and less than or equal to 65 years of age. * Female patients only: * actively practicing a contraceptive method, or * surgically sterilized, or * post-menopausal * Pre-operative Harris Hip Score less than or equal to 70. * Primary surgical hip candidate, suffering from hip pain and/or disability due to degenerative joint disease (inflammatory or non-inflammatory), based on physical examination and history, including the following diagnosis: * non-inflammatory degenerative joint disease (NIDJD), e.g. avascular necrosis or osteoarthritis * inflammatory joint disease (IJD), e.g. rheumatoid arthritis * Patient is willing and able to cooperate in prescribed post-operative therapy. * Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent. * Patient has participated in the Informed Consent process and has signed and IRB approved Informed Consent. Exclusion Criteria: * Patient with an acute, chronic, local or systemic infection. * Patient who is skeletally immature. * Patient with a severe muscular, neural or vascular disease that endangers the involved extremity. * Patient with an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible, including but not limited to: * patient with severe osteopenia * patients with a family history of severe osteoporosis or osteopenia * patients with osteonecrosis or avascular necrosis (AVN) with \> 50% involvement of the femoral head (regardless of FICAT grade) * patients with multiple cysts of the femoral head \> 1cm * Patient with total or partial absence of the muscular of ligamentous apparatus. * Patient has known moderate to severe renal insufficiency. * Patient with a known clinical condition which may interfere with patient outcome, including but not limited to: * immuno-compromised conditions (AIDS), * organ transplant recipient, * high doses of corticosteroids etc * Patient who is severely overweight (BMI \>40) * Operative (ipsilateral) Hip: Patient has a total prosthetic hip replacement device, surface arthroplasty or endoprosthesis. * Contralateral Hip: Patient has had hip replacement, surface arthroplasty or endoprosthesis, within the past 12 months, unless already enrolled in this investigational study. * Patient who is: * a prisoner * mentally incompetent * a known alcohol or drug abuser * anticipated to be non-compliant * Patient who has participated in a study of any other investigational device (drug, device or biologic) within the past 12 months. Exception: previous enrollment in the Durom Hip Resurfacing System clinical study. * Patient has a known allergy to one of the constituents of the implant, e.g. cobalt, chromium, nickel, etc.